Drug profile of giritinib (segatan)

Gilteritinib is a targeted drug used to treat certain types of acute myeloid leukemia (AML). It is primarily used to treat FLT3 mutation-positive adult AML patients, those who FLT3 Patients who are positive for pan>internal dinucleotide binding site (ITD) or tyrosine kinase domain (TKD) mutations.

Giritinib inhibits the activity of FLT3tyrosine kinase, thereby blocking the abnormal activation of the FLT3 signaling pathway and inhibiting the growth and proliferation of leukemia cells. This targeted treatment strategy for FLT3 mutations makes giritinib one of the important drugs in the treatment of AML.

Giritinib is administered orally once daily, usually at a dosage of 120 mg. Patients should follow their doctor's instructions and read the drug instructions carefully before taking giritinib. Depending on the patient's specific condition, the doctor may adjust the dosage or treatment regimen.

The therapeutic effect of giritinib has been verified in clinical trials. For patients with FLT3 mutation-positive AML, its monotherapy has shown significant clinical response and survival advantage. However, some patients may experience adverse reactions, such as nausea, vomiting, fatigue, rash, etc., so the patient's physical condition needs to be closely monitored during treatment and treated as necessary.

In general, giritinib, as a targeted drug targeting FLT3mutation-positive AML, plays an important role in the treatment of AML. It effectively controls AML by inhibiting the abnormal activation of the FLT3 signaling pathway.The progress provides patients with a new treatment option. However, patients should closely follow their doctor's instructions when using giritinib and undergo regular review and monitoring to ensure the effectiveness and safety of the treatment.